Biogen Idec Inc (BIIB) News 294.12 $BIIB
Why Biogen Idec, Vertex Pharmaceuticals, and PG&E Are Today’s 3 Worst Stocks
John Divine, The Motley Fool - Motley Fool - Fri Mar 28, 7:03PM CDT
Eight in 10 sectors advanced in the stock market today, as the S&P 500 Index added eight points, or 0.5%, to end at 1,857. The health-care sector again stood out as an underperformer, continuing a week-long trend that began last Friday. While...
FDA Approves Biogen Idec's ALPROLIX(TM), the First Hemophilia B Therapy to Reduce Bleeding Episodes with Prophylactic Infusions Starting at Least a Week Apart
Business Wire - Fri Mar 28, 5:34PM CDT
---Approved for Adults and Children-
FDA Oks new therapy to prevent hemophilia bleeding
By The Associated Press - AP - Fri Mar 28, 4:56PM CDT
WASHINGTON (AP) — The Food and Drug Administration has approved the first hemophilia B treatment designed to decrease frequency of injections to prevent the excessive bleeding the clotting disorder causes.
After Yesterday's Decline of 5.05%, Biogen Idec Offers Investors Better Value
Comtex SmarTrend(R) - Fri Mar 28, 3:45PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $292.67 to a high of $314.19. Yesterday, the shares fell 5.0%, which took the trading range below the 3-day low of $296.65 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Biogen Idec Falls 5.05% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Mar 28, 3:45PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $292.67 to a high of $314.19. Yesterday, the shares fell 5.0%, which took the trading range below the 3-day low of $296.65 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Rebound Rally Losing More Steam; BitAuto Hangs Tough
at Investor's Business Daily - Fri Mar 28, 1:36PM CDT
Rebound efforts greatly faded late Friday, leaving stocks in mixed territory and on pace for weekly losses. The Nasdaq lost 0.1% after rising as much as 1.3% intraday. The S&P 500 rose 0.2%, down from 1% at its session peak. Meanwhile, the Dow Jones...
Baxter Splitting In Effort To 'Unlock Trapped Value'
at Investor's Business Daily - Thu Mar 27, 5:41PM CDT
Baxter International (BAX) announced Thursday that it will split its biopharma and medical-products businesses into two separate companies by mid-2015, jump-starting its lagging stock with a move that seemed to surprise Wall Street. "We and many...
First Week Of BIIB May 17th Options Trading
at The Street - Thu Mar 27, 11:08AM CDT
Investors in Biogen Idec Inc saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options chain for the new May 17th contracts and identified one put...
Will Baxter International Inc's Split Unlock Shareholder Value?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu Mar 27, 10:47AM CDT
If a strategy has worked before, try it again. Baxter has never been shy about identifying businesses that lie outside its core operating focus and being willing to set them free. Edwards Lifesciences , Caremark, and Allegiance Healthcare (now...
Baxter To Split Into Two Companies; Stock Jumps
at Investor's Business Daily - Thu Mar 27, 10:15AM CDT
Baxter International (BAX) announced Thursday that it will split its biopharma and medical-products businesses into two separate companies by mid-2015. Baxter stock jumped 5% in heavy morning trading in the stock market today. The biopharma arm,...
Critical Alerts For DirecTV, Biogen Idec, Time Warner, Isis Pharmaceuticals, and DreamWorks Animation Released By InvestorsObserver
PR Newswire - Thu Mar 27, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for DTV, BIIB, TWX, ISIS, and DWA.
Therapy Class Overview: Rituximab biosimilar
M2 - Thu Mar 27, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jx6z5c/therapy_class) has announced the addition of the "Therapy Class Overview: Rituximab biosimilar" report to their offering. Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson's Remicade, which is approved for RA, Crohn's disease and several other conditions and had $2 billion in sales in Europe last year. This approval has further increase the optimism of companies developing and marketing biosimilars and the wait for the launch of others in queue Rituxan, Herecptin, Enbrel etc may not be too long. These three drugs alone had worldwide sales of -$21b in 2012. Commercial success of biosimilars will be depend both on affordability and accessibility assuming that the copy molecule is at par on efficacy, safety and similarity with the branded product. Uptake and marketing strategy of Remicade biosimilar will be closely watched by investors as well as companies developing/marketing Biosimilars. In this report, we have analyzed the market opportunity of rituximab biosimilar. Key Topics Covered: 1. Executive Summary 2.Ex-US Experience of Biosimilar launch 3.Introduction - Rituxan/ MabThera (rituximab) 4.Opportunities and Threats for Rituximab Biosimilar 5.A brief on Companies Developing Rituximab Biosimilar 6.Our view on Risk/Reward profile of developing Rituximab Biosimilar 7.About the biosimilar spaceDifferent Technologies Deployed By Biosimilar Players Products Mentioned: - Bio-better - Biogen Idec - CLL - DLBCL - Dr Reddys - Enbrel - GA-101 - Genentech - MabThera - NHL - Obinutuzumab - Ofatumumab - RA - Reditux - Remicade - Rituxan - Roche - Type II - anti-CD20 - biologics - biosimilar - life cycle management - monoclonal antibody - rituximab For more information visit http://www.researchandmarkets.com/research/jx...erapy_clas
Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech
M2 - Thu Mar 27, 4:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rbvwd8/global) has announced the addition of the "Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech" report to their offering. Positive sentiments for the biotech sector have prevailed in the last two to three years, and the authors expect this trend to continue for the next year too. The optimism is based on the continuity in the flow of innovative products from the biotech pipeline, implementation of strategic decisions to improve cost efficiency, strengthen therapeutic leadership, and hedge against generic threats - which all lend stability to the business model. Focus and interest in Orphan diseases remains and Alexion kept everyone guessing on the possible acquisition. BMRN, Alexion are likely candidates to be acquired in this space. In the next five years the distinction between some mature biotech companies and large global pharma may become blurred especially if there is consolidation within the sector. AMGN was the first amongst the peers to declare a dividend and this has raised the bar/expectations from others too. First mAb Biosimilar (Hospira's infliximab - Inflectra) was approved in EU and the pipeline, competition intensifies despite no firm regulatory pathway being defined in the US. This report contains the detailed discussion of the key attributes of leading biotech companies' Acorda, Alexion, Amgen, Biogen Idec, Celgene, Gilead, Regeneron and Vertex. Key Topics Covered: 1. Acorda Therapeutics - Pipeline of NDDS Drugs targeting Niche Indications 2. Alexion Pharma - Focus on Innovative Drugs for Orphan/ Ultra-rare Diseases with No Competition Visible! 3. Amgen - Late-Stage Pipeline Carries Potential to Counteract Expected Headwinds 4. Biogen Idec - Near-Term Growth Prospects Driven by Core Business New Product Launches 5. Celgene - Innovative Strategies for Long Term Gains 6. Regeneron - Label Expansion Sustains Eylea's Growth Momentum Late Stage Pipeline 7. Vertex Pharma - Focus Shift to Cystic Fibrosis and Niche Indications Companies Mentioned: - Acorada - Alexion - Amgen - Biogen Idec - Celgene - Gilead Sciences - Regeneron - Vertex Pharma For more information visit http://www.researchandmarkets.com/research/rbvwd8/global
BIOGEN IDEC
at Investor's Business Daily - Wed Mar 26, 5:46PM CDT
BIOGEN IDEC (BIIB) and Amgen (AMGN) both had coverage initiated with overweight ratings by Morgan Stanley, with a 140 price target for Biogen and 140 for Amgen. Amgen rose 0.5% to 120.79.
Pharmaceutical Executive to Unveil Brand of the Year Award Recipients at iPharma 2014: CBI's Marketing Innovation Summit
PR Newswire - Wed Mar 26, 11:11AM CDT
CBI is pleased to announce that Pharmaceutical Executive will reveal its prestigious Brand of the Year Award during iPharma 2014 - industry's leading marketing innovation summit - taking place May 8-9, 2014 in New York, NY. iPharma 2014 is the most compelling and comprehensive life sciences meeting, uniting key stakeholders in the world of digital marketing, strategy, branding, innovation, media, and IT to share the latest trends and real-world approaches to developing effective and innovative promotional campaigns. Executives from Arbor Pharmaceuticals, Auxilium, Bayer, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, CSL Behring, EMD Serono, GE Healthcare, Inspirion, Lilly, Lundbeck, Merck, Novartis, Ova Science, Pfizer, Purdue, Roche, Shire, UCB, Voltarra Pharmaceuticals and many other leading organizations round out the highly anticipated agenda.
Biotech Stock Roundup: GILD Letter Triggers Major Selloff - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 9:13AM CDT
Are the good days over for the biotech sector or is this just a correction?
1 Big Reason to Doubt the Biotech Bubble Chorus
Keith Speights, The Motley Fool - Motley Fool - Wed Mar 26, 8:30AM CDT
Raise your hand if you've heard the words "biotech" and "bubble" used in the same sentence recently. Observers from virtually every corner have joined the chorus singing the blues about the biotech sector. Some might even be humming a funeral dirge....
Drug Approvals, Stock Price Movements, and New Tools for Standardization - Analyst Notes on Biogen Idec, Alexion, Actavis, Thermo Fisher Scientific, and Medtronic
PR Newswire - Wed Mar 26, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Actavis plc Ordinary Shares (NYSE: ACT), Thermo Fisher Scientific Inc. (NYSE: TMO), and Medtronic, Inc. (NYSE: MDT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Why Biogen Idec, Vertex Pharmaceuticals, and PG&E Are Today’s 3 Worst Stocks
John Divine, The Motley Fool - Motley Fool - Fri Mar 28, 7:03PM CDT
Eight in 10 sectors advanced in the stock market today, as the S&P 500 Index added eight points, or 0.5%, to end at 1,857. The health-care sector again stood out as an underperformer, continuing a week-long trend that began last Friday. While...
FDA Approves Biogen Idec's ALPROLIX(TM), the First Hemophilia B Therapy to Reduce Bleeding Episodes with Prophylactic Infusions Starting at Least a Week Apart
Business Wire - Fri Mar 28, 5:34PM CDT
---Approved for Adults and Children-
FDA Oks new therapy to prevent hemophilia bleeding
By The Associated Press - AP - Fri Mar 28, 4:56PM CDT
WASHINGTON (AP) — The Food and Drug Administration has approved the first hemophilia B treatment designed to decrease frequency of injections to prevent the excessive bleeding the clotting disorder causes.
After Yesterday's Decline of 5.05%, Biogen Idec Offers Investors Better Value
Comtex SmarTrend(R) - Fri Mar 28, 3:45PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $292.67 to a high of $314.19. Yesterday, the shares fell 5.0%, which took the trading range below the 3-day low of $296.65 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Biogen Idec Falls 5.05% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Mar 28, 3:45PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $292.67 to a high of $314.19. Yesterday, the shares fell 5.0%, which took the trading range below the 3-day low of $296.65 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Rebound Rally Losing More Steam; BitAuto Hangs Tough
at Investor's Business Daily - Fri Mar 28, 1:36PM CDT
Rebound efforts greatly faded late Friday, leaving stocks in mixed territory and on pace for weekly losses. The Nasdaq lost 0.1% after rising as much as 1.3% intraday. The S&P 500 rose 0.2%, down from 1% at its session peak. Meanwhile, the Dow Jones...
Baxter Splitting In Effort To 'Unlock Trapped Value'
at Investor's Business Daily - Thu Mar 27, 5:41PM CDT
Baxter International (BAX) announced Thursday that it will split its biopharma and medical-products businesses into two separate companies by mid-2015, jump-starting its lagging stock with a move that seemed to surprise Wall Street. "We and many...
First Week Of BIIB May 17th Options Trading
at The Street - Thu Mar 27, 11:08AM CDT
Investors in Biogen Idec Inc saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options chain for the new May 17th contracts and identified one put...
Will Baxter International Inc's Split Unlock Shareholder Value?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu Mar 27, 10:47AM CDT
If a strategy has worked before, try it again. Baxter has never been shy about identifying businesses that lie outside its core operating focus and being willing to set them free. Edwards Lifesciences , Caremark, and Allegiance Healthcare (now...
Baxter To Split Into Two Companies; Stock Jumps
at Investor's Business Daily - Thu Mar 27, 10:15AM CDT
Baxter International (BAX) announced Thursday that it will split its biopharma and medical-products businesses into two separate companies by mid-2015. Baxter stock jumped 5% in heavy morning trading in the stock market today. The biopharma arm,...
Critical Alerts For DirecTV, Biogen Idec, Time Warner, Isis Pharmaceuticals, and DreamWorks Animation Released By InvestorsObserver
PR Newswire - Thu Mar 27, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for DTV, BIIB, TWX, ISIS, and DWA.
Therapy Class Overview: Rituximab biosimilar
M2 - Thu Mar 27, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jx6z5c/therapy_class) has announced the addition of the "Therapy Class Overview: Rituximab biosimilar" report to their offering. Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson's Remicade, which is approved for RA, Crohn's disease and several other conditions and had $2 billion in sales in Europe last year. This approval has further increase the optimism of companies developing and marketing biosimilars and the wait for the launch of others in queue Rituxan, Herecptin, Enbrel etc may not be too long. These three drugs alone had worldwide sales of -$21b in 2012. Commercial success of biosimilars will be depend both on affordability and accessibility assuming that the copy molecule is at par on efficacy, safety and similarity with the branded product. Uptake and marketing strategy of Remicade biosimilar will be closely watched by investors as well as companies developing/marketing Biosimilars. In this report, we have analyzed the market opportunity of rituximab biosimilar. Key Topics Covered: 1. Executive Summary 2.Ex-US Experience of Biosimilar launch 3.Introduction - Rituxan/ MabThera (rituximab) 4.Opportunities and Threats for Rituximab Biosimilar 5.A brief on Companies Developing Rituximab Biosimilar 6.Our view on Risk/Reward profile of developing Rituximab Biosimilar 7.About the biosimilar spaceDifferent Technologies Deployed By Biosimilar Players Products Mentioned: - Bio-better - Biogen Idec - CLL - DLBCL - Dr Reddys - Enbrel - GA-101 - Genentech - MabThera - NHL - Obinutuzumab - Ofatumumab - RA - Reditux - Remicade - Rituxan - Roche - Type II - anti-CD20 - biologics - biosimilar - life cycle management - monoclonal antibody - rituximab For more information visit http://www.researchandmarkets.com/research/jx...erapy_clas
Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech
M2 - Thu Mar 27, 4:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rbvwd8/global) has announced the addition of the "Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech" report to their offering. Positive sentiments for the biotech sector have prevailed in the last two to three years, and the authors expect this trend to continue for the next year too. The optimism is based on the continuity in the flow of innovative products from the biotech pipeline, implementation of strategic decisions to improve cost efficiency, strengthen therapeutic leadership, and hedge against generic threats - which all lend stability to the business model. Focus and interest in Orphan diseases remains and Alexion kept everyone guessing on the possible acquisition. BMRN, Alexion are likely candidates to be acquired in this space. In the next five years the distinction between some mature biotech companies and large global pharma may become blurred especially if there is consolidation within the sector. AMGN was the first amongst the peers to declare a dividend and this has raised the bar/expectations from others too. First mAb Biosimilar (Hospira's infliximab - Inflectra) was approved in EU and the pipeline, competition intensifies despite no firm regulatory pathway being defined in the US. This report contains the detailed discussion of the key attributes of leading biotech companies' Acorda, Alexion, Amgen, Biogen Idec, Celgene, Gilead, Regeneron and Vertex. Key Topics Covered: 1. Acorda Therapeutics - Pipeline of NDDS Drugs targeting Niche Indications 2. Alexion Pharma - Focus on Innovative Drugs for Orphan/ Ultra-rare Diseases with No Competition Visible! 3. Amgen - Late-Stage Pipeline Carries Potential to Counteract Expected Headwinds 4. Biogen Idec - Near-Term Growth Prospects Driven by Core Business New Product Launches 5. Celgene - Innovative Strategies for Long Term Gains 6. Regeneron - Label Expansion Sustains Eylea's Growth Momentum Late Stage Pipeline 7. Vertex Pharma - Focus Shift to Cystic Fibrosis and Niche Indications Companies Mentioned: - Acorada - Alexion - Amgen - Biogen Idec - Celgene - Gilead Sciences - Regeneron - Vertex Pharma For more information visit http://www.researchandmarkets.com/research/rbvwd8/global
BIOGEN IDEC
at Investor's Business Daily - Wed Mar 26, 5:46PM CDT
BIOGEN IDEC (BIIB) and Amgen (AMGN) both had coverage initiated with overweight ratings by Morgan Stanley, with a 140 price target for Biogen and 140 for Amgen. Amgen rose 0.5% to 120.79.
Pharmaceutical Executive to Unveil Brand of the Year Award Recipients at iPharma 2014: CBI's Marketing Innovation Summit
PR Newswire - Wed Mar 26, 11:11AM CDT
CBI is pleased to announce that Pharmaceutical Executive will reveal its prestigious Brand of the Year Award during iPharma 2014 - industry's leading marketing innovation summit - taking place May 8-9, 2014 in New York, NY. iPharma 2014 is the most compelling and comprehensive life sciences meeting, uniting key stakeholders in the world of digital marketing, strategy, branding, innovation, media, and IT to share the latest trends and real-world approaches to developing effective and innovative promotional campaigns. Executives from Arbor Pharmaceuticals, Auxilium, Bayer, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, CSL Behring, EMD Serono, GE Healthcare, Inspirion, Lilly, Lundbeck, Merck, Novartis, Ova Science, Pfizer, Purdue, Roche, Shire, UCB, Voltarra Pharmaceuticals and many other leading organizations round out the highly anticipated agenda.
Biotech Stock Roundup: GILD Letter Triggers Major Selloff - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 9:13AM CDT
Are the good days over for the biotech sector or is this just a correction?
1 Big Reason to Doubt the Biotech Bubble Chorus
Keith Speights, The Motley Fool - Motley Fool - Wed Mar 26, 8:30AM CDT
Raise your hand if you've heard the words "biotech" and "bubble" used in the same sentence recently. Observers from virtually every corner have joined the chorus singing the blues about the biotech sector. Some might even be humming a funeral dirge....
Drug Approvals, Stock Price Movements, and New Tools for Standardization - Analyst Notes on Biogen Idec, Alexion, Actavis, Thermo Fisher Scientific, and Medtronic
PR Newswire - Wed Mar 26, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Actavis plc Ordinary Shares (NYSE: ACT), Thermo Fisher Scientific Inc. (NYSE: TMO), and Medtronic, Inc. (NYSE: MDT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
